Bamco Inc Argenx Se Transaction History

Bamco Inc

$36.8 Billion
Q3 2024

A detailed history of Bamco Inc transactions in Argenx Se stock. As of the latest transaction made, Bamco Inc holds 250,304 shares of ARGX stock, worth $141 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares

250,304

Previous 261,478 4.27%

Holding current value

$141 Million

Previous $112 Million 20.72%

% of portfolio

0.37%

Previous 0.33%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$434.22 - $551.9 $4.85 Million - $6.17 Million	-11,174 Reduced 4.27%	250,304 $136 Million
Q2 2024 Aug 14, 2024	SELL	$356.01 - $451.55 $1.85 Million - $2.35 Million	-5,196 Reduced 1.95%	261,478 $112 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $7.39 Million - $8.56 Million	-20,705 Reduced 7.2%	266,674 $105 Million
Q4 2023 Feb 14, 2024	SELL	$338.91 - $506.01 $207,412 - $309,678	-612 Reduced 0.21%	287,379 $109 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $13.9 Million - $20.7 Million	37,723 Added 15.07%	287,991 $142 Million
Q2 2023 Aug 14, 2023	BUY	$360.14 - $422.58 $472,863 - $554,847	1,313 Added 0.53%	250,268 $97.5 Million
Q1 2023 May 15, 2023	SELL	$334.23 - $403.65 $38.5 Million - $46.6 Million	-115,331 Reduced 31.66%	248,955 $92.8 Million
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $18.1 Million - $21.3 Million	-52,915 Reduced 12.68%	364,286 $138 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $1.18 Million - $1.36 Million	-3,444 Reduced 0.82%	417,201 $147 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $21.8 Million - $30.6 Million	-80,694 Reduced 16.1%	420,645 $159 Million
Q1 2022 May 13, 2022	SELL	$254.45 - $351.06 $15.8 Million - $21.8 Million	-62,196 Reduced 11.04%	501,339 $158 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $3.5 Million - $4.54 Million	12,869 Added 2.34%	563,535 $197 Million
Q3 2021 Nov 12, 2021	BUY	$295.0 - $350.58 $724,225 - $860,673	2,455 Added 0.45%	550,666 $166 Million
Q2 2021 Aug 13, 2021	BUY	$257.11 - $319.92 $14 Million - $17.4 Million	54,484 Added 11.04%	548,211 $165 Million
Q1 2021 May 19, 2021	BUY	$268.3 - $380.31 $32.6 Million - $46.1 Million	121,329 Added 32.58%	493,727 $136 Million
Q4 2020 Feb 12, 2021	BUY	$248.13 - $308.36 $19 Million - $23.6 Million	76,654 Added 25.92%	372,398 $110 Million
Q3 2020 Nov 13, 2020	BUY	$215.51 - $272.51 $6.28 Million - $7.93 Million	29,118 Added 10.92%	295,744 $77.6 Million
Q2 2020 Aug 14, 2020	BUY	$127.44 - $232.72 $6.42 Million - $11.7 Million	50,350 Added 23.28%	266,626 $60.1 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $8.84 Million - $13.4 Million	-81,229 Reduced 27.3%	216,276 $28.5 Million
Q4 2019 Feb 18, 2020	BUY	$106.59 - $164.21 $1.38 Million - $2.13 Million	12,962 Added 4.56%	297,505 $47.8 Million
Q3 2019 Nov 14, 2019	BUY	$113.31 - $150.51 $11 Million - $14.6 Million	96,811 Added 51.57%	284,543 $32.4 Million
Q2 2019 Aug 15, 2019	SELL	$115.0 - $141.58 $1.67 Million - $2.06 Million	-14,561 Reduced 7.2%	187,732 $26.6 Million
Q1 2019 May 15, 2019	SELL	$98.85 - $134.59 $491,482 - $669,181	-4,972 Reduced 2.4%	202,293 $25.3 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $671,600 - $1.16 Million	10,525 Added 5.35%	207,265 $19.9 Million
Q3 2018 Nov 14, 2018	BUY	$75.5 - $96.63 $1.31 Million - $1.67 Million	17,312 Added 9.65%	196,740 $14.9 Million
Q2 2018 Aug 14, 2018	BUY	$74.84 - $100.16 $2.31 Million - $3.1 Million	30,917 Added 20.82%	179,428 $14.9 Million
Q1 2018 May 09, 2018	SELL	$56.95 - $85.19 $56,950 - $85,190	-1,000 Reduced 0.67%	148,511 $11.9 Million
Q4 2017 Feb 14, 2018	BUY	$22.57 - $63.56 $3.37 Million - $9.5 Million	149,511	149,511 $9.44 Million

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bamco Inc , based on Form 13F filings with the SEC.

News

Stay updated on Bamco Inc with notifications on news.

Account